Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: May 7, 2009

Premium

Title: RNAi Modulation of ApoB and Uses Thereof

Number: 7,528,118

Filed: Sept. 26, 2005

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

According the patent's abstract, the invention "relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the down-regulation of apolipoprotein B by chemically modified oligonucleotides."


Title: Novel Gene-Therapy Approach for Treating the Metabolic Disorder Obesity

Number: 20090110661

Filed: Oct. 30, 2008

Inventor: Sergey Musatov, Neurologix

The patent application, its abstract states, "relates to novel methods for treating obesity. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic dysfunction, such as diabetes, obesity, high blood pressure, and atherogenic dyslipidemia."

The application also "pertains to the use of vectors such as a recombinant adeno-associated virus to deliver a gene that can increase or decrease expression of a therapeutic protein of interest, e.g., in cells in a specific region of the brain associated with metabolic dysfunction," the abstract adds. "The … application also discloses the use of vectors such as a recombinant adeno-associated virus for the delivery of small interference RNAs capable of decreasing expression of a deleterious protein involved in the disorder."